Indicators of amyloid burden in a population-based study of cognitively normal elderly

Michelle M Mielke, Heather J. Wiste, Stephen D. Weigand, David S Knopman, Val Lowe, Rosebud O Roberts, Yonas Endale Geda, Dana M. Swenson-Dravis, Bradley F Boeve, Matthew L. Senjem, Prashanthi D Vemuri, Ronald Carl Petersen, Clifford R Jr. Jack

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Objectives: Secondary prevention trials in subjects with preclinical Alzheimer disease may require documentation of brain amyloidosis. The identification of inexpensive and noninvasive screening variables that can identify individuals who have significant amyloid accumulation would reduce screening costs. Methods: A total of 483 cognitively normal (CN) individuals, aged 70-92 years, from the population-based Mayo Clinic Study of Aging, underwent Pittsburgh compound B (PiB)-PET imaging. Logistic regression determined whether age, sex, APOE genotype, family history, or cognitive performance was associated with odds of a PiB retention ratio <1.4 and <1.5. Area under the receiver operating characteristic curve (AUROC) evaluated the discrimination between PiBpositive and -negative subjects. For each characteristic, we determined the number needed to screen in each age group (70-79 and 80-89) to identify 100 participants with PiB <1.4 or <1.5. Results: A total of 211 (44%) individuals had PiB <1.4 and 151 (31%) <1.5. In univariate and multivariate models, discrimination was modest (AUROC ̃0.6-0.7). Multivariately, age and APOE best predicted odds of PiB <1.4 and <1.5. Subjective memory complaints were similar to cognitive test performance in predicting PiB <1.5. Indicators of PiB positivity varied with age. Screening APOE ε4 carriers alone reduced the number needed to screen to enroll 100 subjects with PIB <1.5 by 48% in persons aged 70-79 and 33% in those aged 80-89. Conclusions: Age and APOE genotype are useful predictors of the likelihood of significant amyloid accumulation, but discrimination is modest. Nonetheless, these results suggest that inexpensive and noninvasive measures could significantly reduce the number of CN individuals needed to screen to enroll a given number of amyloid-positive subjects.

Original languageEnglish (US)
Pages (from-to)1570-1577
Number of pages8
JournalNeurology
Volume79
Issue number15
DOIs
StatePublished - Oct 9 2012

Fingerprint

Amyloid
Population
ROC Curve
Genotype
Amyloidosis
Secondary Prevention
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
Burden
Pittsburgh
Documentation
Alzheimer Disease
Age Groups
Logistic Models
Costs and Cost Analysis
Brain
Discrimination (Psychology)
Screening

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Indicators of amyloid burden in a population-based study of cognitively normal elderly. / Mielke, Michelle M; Wiste, Heather J.; Weigand, Stephen D.; Knopman, David S; Lowe, Val; Roberts, Rosebud O; Geda, Yonas Endale; Swenson-Dravis, Dana M.; Boeve, Bradley F; Senjem, Matthew L.; Vemuri, Prashanthi D; Petersen, Ronald Carl; Jack, Clifford R Jr.

In: Neurology, Vol. 79, No. 15, 09.10.2012, p. 1570-1577.

Research output: Contribution to journalArticle

@article{8c9c171e9b314d2aa62121e266f00c33,
title = "Indicators of amyloid burden in a population-based study of cognitively normal elderly",
abstract = "Objectives: Secondary prevention trials in subjects with preclinical Alzheimer disease may require documentation of brain amyloidosis. The identification of inexpensive and noninvasive screening variables that can identify individuals who have significant amyloid accumulation would reduce screening costs. Methods: A total of 483 cognitively normal (CN) individuals, aged 70-92 years, from the population-based Mayo Clinic Study of Aging, underwent Pittsburgh compound B (PiB)-PET imaging. Logistic regression determined whether age, sex, APOE genotype, family history, or cognitive performance was associated with odds of a PiB retention ratio <1.4 and <1.5. Area under the receiver operating characteristic curve (AUROC) evaluated the discrimination between PiBpositive and -negative subjects. For each characteristic, we determined the number needed to screen in each age group (70-79 and 80-89) to identify 100 participants with PiB <1.4 or <1.5. Results: A total of 211 (44{\%}) individuals had PiB <1.4 and 151 (31{\%}) <1.5. In univariate and multivariate models, discrimination was modest (AUROC ̃0.6-0.7). Multivariately, age and APOE best predicted odds of PiB <1.4 and <1.5. Subjective memory complaints were similar to cognitive test performance in predicting PiB <1.5. Indicators of PiB positivity varied with age. Screening APOE ε4 carriers alone reduced the number needed to screen to enroll 100 subjects with PIB <1.5 by 48{\%} in persons aged 70-79 and 33{\%} in those aged 80-89. Conclusions: Age and APOE genotype are useful predictors of the likelihood of significant amyloid accumulation, but discrimination is modest. Nonetheless, these results suggest that inexpensive and noninvasive measures could significantly reduce the number of CN individuals needed to screen to enroll a given number of amyloid-positive subjects.",
author = "Mielke, {Michelle M} and Wiste, {Heather J.} and Weigand, {Stephen D.} and Knopman, {David S} and Val Lowe and Roberts, {Rosebud O} and Geda, {Yonas Endale} and Swenson-Dravis, {Dana M.} and Boeve, {Bradley F} and Senjem, {Matthew L.} and Vemuri, {Prashanthi D} and Petersen, {Ronald Carl} and Jack, {Clifford R Jr.}",
year = "2012",
month = "10",
day = "9",
doi = "10.1212/WNL.0b013e31826e2696",
language = "English (US)",
volume = "79",
pages = "1570--1577",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "15",

}

TY - JOUR

T1 - Indicators of amyloid burden in a population-based study of cognitively normal elderly

AU - Mielke, Michelle M

AU - Wiste, Heather J.

AU - Weigand, Stephen D.

AU - Knopman, David S

AU - Lowe, Val

AU - Roberts, Rosebud O

AU - Geda, Yonas Endale

AU - Swenson-Dravis, Dana M.

AU - Boeve, Bradley F

AU - Senjem, Matthew L.

AU - Vemuri, Prashanthi D

AU - Petersen, Ronald Carl

AU - Jack, Clifford R Jr.

PY - 2012/10/9

Y1 - 2012/10/9

N2 - Objectives: Secondary prevention trials in subjects with preclinical Alzheimer disease may require documentation of brain amyloidosis. The identification of inexpensive and noninvasive screening variables that can identify individuals who have significant amyloid accumulation would reduce screening costs. Methods: A total of 483 cognitively normal (CN) individuals, aged 70-92 years, from the population-based Mayo Clinic Study of Aging, underwent Pittsburgh compound B (PiB)-PET imaging. Logistic regression determined whether age, sex, APOE genotype, family history, or cognitive performance was associated with odds of a PiB retention ratio <1.4 and <1.5. Area under the receiver operating characteristic curve (AUROC) evaluated the discrimination between PiBpositive and -negative subjects. For each characteristic, we determined the number needed to screen in each age group (70-79 and 80-89) to identify 100 participants with PiB <1.4 or <1.5. Results: A total of 211 (44%) individuals had PiB <1.4 and 151 (31%) <1.5. In univariate and multivariate models, discrimination was modest (AUROC ̃0.6-0.7). Multivariately, age and APOE best predicted odds of PiB <1.4 and <1.5. Subjective memory complaints were similar to cognitive test performance in predicting PiB <1.5. Indicators of PiB positivity varied with age. Screening APOE ε4 carriers alone reduced the number needed to screen to enroll 100 subjects with PIB <1.5 by 48% in persons aged 70-79 and 33% in those aged 80-89. Conclusions: Age and APOE genotype are useful predictors of the likelihood of significant amyloid accumulation, but discrimination is modest. Nonetheless, these results suggest that inexpensive and noninvasive measures could significantly reduce the number of CN individuals needed to screen to enroll a given number of amyloid-positive subjects.

AB - Objectives: Secondary prevention trials in subjects with preclinical Alzheimer disease may require documentation of brain amyloidosis. The identification of inexpensive and noninvasive screening variables that can identify individuals who have significant amyloid accumulation would reduce screening costs. Methods: A total of 483 cognitively normal (CN) individuals, aged 70-92 years, from the population-based Mayo Clinic Study of Aging, underwent Pittsburgh compound B (PiB)-PET imaging. Logistic regression determined whether age, sex, APOE genotype, family history, or cognitive performance was associated with odds of a PiB retention ratio <1.4 and <1.5. Area under the receiver operating characteristic curve (AUROC) evaluated the discrimination between PiBpositive and -negative subjects. For each characteristic, we determined the number needed to screen in each age group (70-79 and 80-89) to identify 100 participants with PiB <1.4 or <1.5. Results: A total of 211 (44%) individuals had PiB <1.4 and 151 (31%) <1.5. In univariate and multivariate models, discrimination was modest (AUROC ̃0.6-0.7). Multivariately, age and APOE best predicted odds of PiB <1.4 and <1.5. Subjective memory complaints were similar to cognitive test performance in predicting PiB <1.5. Indicators of PiB positivity varied with age. Screening APOE ε4 carriers alone reduced the number needed to screen to enroll 100 subjects with PIB <1.5 by 48% in persons aged 70-79 and 33% in those aged 80-89. Conclusions: Age and APOE genotype are useful predictors of the likelihood of significant amyloid accumulation, but discrimination is modest. Nonetheless, these results suggest that inexpensive and noninvasive measures could significantly reduce the number of CN individuals needed to screen to enroll a given number of amyloid-positive subjects.

UR - http://www.scopus.com/inward/record.url?scp=84867528523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867528523&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e31826e2696

DO - 10.1212/WNL.0b013e31826e2696

M3 - Article

C2 - 22972644

AN - SCOPUS:84867528523

VL - 79

SP - 1570

EP - 1577

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 15

ER -